Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Second TNF Blocker in Axial Spondyloarthritis
NCT03445845Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Dec 2018
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of secukinumab in axial spondyloarthritis (axSpA), sponsored by CHU Saint-Etienne. Started Dec 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03445845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445845.